Slingshot members are tracking this event:
Data from Novartis' (NVS) RTH258 (brolucizumab) Phase 3 study in nAMD patients released
Slingshot Insights Explained
Jun 20, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Neovascular Amd, Rth258, Brolucizumab